Low plasma atrial natriuretic peptide: A new piece in the puzzle of polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages 4882-4889

  Lauria, Patricia B M ^a   Del Puerto, Helen L ^a   Reis, Adelina M ^a   Candido, Ana L ^b   Reis, Fernando M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Laboratory of Endocrinology   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; ENZYME IMMUNOASSAY; FEMALE; HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE INDEX; HUMAN; INSULIN SENSITIVITY; LIPID ACCUMULATION PRODUCT INDEX; METABOLIC PARAMETERS; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RATING SCALE; TEACHING HOSPITAL; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADIPOSITY; ADULT; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; FEMALE; HOSPITALS, TEACHING; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; NATRIURETIC PEPTIDE, BRAIN; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME;

EID: 84889770954     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2141     Document Type: Article

References (46)

1. Stein IF, Leventhal ML. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181-191.
2. Zawadeski JK, Dunaif A. Diagnostic criteria for PCOS: towards a more rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam MR, eds. PCOS. Boston, MA: Blackwell Scientific; 1992: 377-384.
3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81:19-25.
4. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004;60:1-17.
5. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685-697.
6. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update. 2008;14:367- 378.
7. Chazenbalk G, Trivax BS, Yildiz BO, et al. Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-α. J Clin Endocrinol Metab. 2010;95:935-942.
8. Moro C, Berlan M. Cardiovascular and metabolic effects of natriuretic peptides. Fundam Clin Pharmacol. 2006;20:41-49.
9. Sengenès C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000;14:1345-1351.
10. Moro C, Galitzky J, Sengenes C, Crampes F, Lafontan M, Berlan M. Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway inhumanfat cells. J Pharmacol Exp Ther. 2004;308:984-992.
11. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation. 2007;115:1345-1353.
12. Verspohl EJ, Bernemann IK. Atrial natriuretic peptide (ANP)-induced inhibition of glucagon secretion: mechanism of action in isolated rat pancreatic islets. Peptides. 1996;17:1023-1029.
13. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594-600.
14. Khan AM, Cheng S, Magnusson M, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two communitybased studies. J Clin Endocrinol Metab. 2011;96:3242-3249.
15. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439-451.
16. Mannerås-Holm L, Leonhardt H, Kullberg J, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011;96:E304-E311.
17. Toulis KA, Goulis DG, Farmakiotis D, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009;15:297-307.
18. Wickham EP 3rd, Cheang KI, Clore JN, Baillargeon JP, Nestler JE. Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome. Metabolism. 2011;60:366-372.
19. O'Connor A, Phelan N, Tun TK, Boran G, Gibney J, Roche HM. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocrinol Metab. 2010;95:1378-385.
20. Birkenfeld AL, Boschmann M, Engeli S, et al. Atrial natriuretic peptide and adiponectin interactions in man. PloSOne. 2012;7:e43238.
21. Deitel M, Gawdat K, Melissas J. Reporting weight loss 2007. Obes Surg. 2007;17:565-568.
22. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981; 140:815-830.
23. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: 1206-1252.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma lucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
26. Wiltgen D, Benedetto IG, Mastella LS, Spritzer PM. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod. 2009;24:1726-1731.
27. Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, Ermetice MN. The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res Clin Pract. 2006;72:219-220.
28. Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry RR. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab. 2009;94:157-163.
29. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 1992;41:1257-1266.
30. Nannipieri M, Seghieri G, Catalano C, Prontera T, Baldi S, Ferrannini E. Defective regulation and action of atrial natriuretic peptide in type 2 diabetes. Horm Metab Res. 2002;34:265-270.
31. Gerbes AL, Dagnino L, Nguyen T, Nemer M.Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. J Clin Endocrinol Metab. 1994;78:1307-1311.
32. Dineva J, Vangelov I, Nikolov G, Gulenova D, Ivanova M. Atrial natriuretic peptide is an antiapoptotic factor for human granulose luteinized cells with impact on the results of COH/IVF in women undergoing IVF program. J Obstet Gynaecol Res. 2011;37:511-519.
33. Johnson KM,Hughes FM Jr, Fong YY,Mathur RS, Williamson HO, Gorospe WC. Effects of atrial natriuretic peptide on rat ovarian granulosa cell steroidogenesis in vitro. Am J Reprod Immunol. 1994;31:163-168.
34. Sarzani R, Dessì-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Clin Invest. 1996;19:581-585.
35. Sarzani R, Paci VM,Zingaretti CM,et al. Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue. J Hypertens. 1995;13:1241-1246.
36. Crandall DL, Ferraro GD, Cervoni P. Effect of experimental obesity and subsequent weight reduction upon circulating atrial natriuretic peptide. Proc Soc Exp Biol Med. 1989;191:352-356.
37. Bordicchia M,Liu D, Amri EZ, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122:1022-1036.
38. Olszanecka-Glinianowicz M, Kuglin D, Dbkowska-Hu A, Skałba P. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011; 154:51-56.
39. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86:3815-3819.
40. Kuo SM, Halpern MM. Lack of association between body mass index and plasma adiponectin levels in healthy adults. Int J Obes (Lond). 2011;35:1487-1494.
41. Tsukamoto O, Fujita M,Kato M,et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J AmColl Cardiol. 2009;53:2070-2077.
42. Hernandez-Yero A, Santana Perez F, Ovies Carballo G, Cabrera- Rode E. Diamel therapy in polycystic ovary syndrome reduces hyperinsulinaemia insulin resistance, and hyperandrogenaemia. Int J Endocrinol. 2012;2012:382719
43. Berneis K, Rizzo M, Lazzaroni V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:186-189.
44. Xiang SK, Hua F, Tang Y, Jiang XH, Zhuang Q, Qian FJ. Relationship between serum lipoprotein ratios and insulin resistance in polycystic ovary syndrome. Int J Endocrinol. 2012;2012:173281.
45. Yeko TR, Rao PS, Parsons AK, Mayer JC, Graham LB, Maroulis GB. Atrial natriuretic peptide, oestradiol and progesterone in women undergoing spontaneous and gonadotrophin- stimulated ovulatory cycles. Hum Reprod. 1995;10:2872-2874.
46. Bisson DL, Dunster GD, O'Hare JP, Hampton D, Penney MD. Renal sodium retention does not occur during the luteal phase of the menstrual cycle in normal women. Br J Obstet Gynaecol. 1992;99: 247-252.